Alnylam Pharmaceuticals, Inc. vs Vertex Pharmaceuticals Incorpor
A head-to-head of Alnylam Pharmaceuticals, Inc. (ALNY) and Vertex Pharmaceuticals Incorpor (VRTX) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ALNY | VRTX |
|---|---|---|
| Market Cap | $41.87B | $108.72B |
| P/E (TTM) | 79.94 | 25.41 |
| Forward P/E | 21.24 | 20.21 |
| P/S | 9.77 | 9.03 |
| P/B | 36.31 | 5.62 |
| EV/EBITDA | 44.53 | 21.08 |
| Dividend Yield | — | — |
| Profit Margin | 13.46% | 35.51% |
| Gross Margin | 81.64% | 86.24% |
| Operating Margin | 13.51% | 37.95% |
| Revenue Growth (YoY) | +96.43% | +7.82% |
| FCF Yield | 1.54% | 3.36% |
| Debt / Equity | 93.86 | 10.26 |
| Current Ratio | 3.13 | 3.02 |
Share:
Compare Alnylam Pharmaceuticals, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.